Introduction
Methods
Study Population
Data Collection
Atrial Fibrillation
Statistical Analysis
Results
All | Statin users | Non-statin users |
P
| |
---|---|---|---|---|
N = 272 |
N = 79 |
N = 193 | ||
Age (years) | 65 ± 11 | 65 ± 11 | 65 ± 11 | 0.510 |
Male (%) | 142 (52) | 41 (52) | 101 (52) | 0.948 |
Previous history, n (%) | ||||
NYHA I | 37 (14) | 8 (11) | 29 (15) | |
NYHA II | 55 (21) | 16 (22) | 39 (21) | |
NYHA III | 146 (56) | 41 (56) | 105 (56) | |
NYHA IV | 23 (9) | 8 (11) | 15 (8) | 0.728 |
AF | 54 (20) | 17 (22) | 37 (19) | 0.659 |
PCI | 37 (14) | 20 (25) | 17 (9) | <0.001 |
CABG | 26 (10) | 19 (24) | 7 (4) | <0.001 |
Valve surgery | 23 (9) | 10 (13) | 13 (7) | 0.111 |
Diabetes | 27 (10) | 17 (22) | 10 (5) | <0.001 |
COPD | 31 (12) | 8 (11) | 23 (12) | 0.743 |
Hypertension | 110 (40) | 37 (47) | 73 (38) | 0.169 |
Pulmonary hypertension | 107 (41) | 30 (39) | 77 (42) | 0.641 |
Laboratory | ||||
Haemoglobin (mmol/l) | 8.4 ± 1.0 | 8.4 ± 1.0 | 8.4 ± 1.0 | 0.741 |
Creatinine (μmol/l) | 98 (78–104)a
| 106 (74–107)a
| 94 (79–103)a
| 0.604b
|
Cholesterol (mg/dl) | 212 ± 49 | 190 ± 43 | 222 ± 48 | <0.001 |
Echocardiography | ||||
Left atrial size (mm) | 48 ± 8 | 49 ± 7 | 48 ± 8 | 0.894 |
LVEF (%) | 57 ± 12 | 56 ± 11 | 58 ± 12 | 0.349 |
Drugs, n (%) | ||||
ACE-I | 127 (47) | 41 (52) | 86 (45) | 0.271 |
Beta-blocker | 87 (32) | 40 (51) | 47 (24) | <0.001 |
AAD | 44 (16) | 12 (15) | 32 (17) | 0.777 |
Surgery, n (%) | ||||
Emergency | 12 (4) | 3 (4) | 9 (5) | 0.752 |
Aortic valve | 189 (70) | 57 (72) | 132 (68) | 0.541 |
Mitral valve | 78 (29) | 19 (24) | 59 (31) | 0.280 |
>1 valve | 21 (8) | 2 (3) | 19 (10) | 0.043 |
Mechanical prosthesis | 201 (75) | 62 (81) | 139 (72) | 0.166 |
ECC time (min) | 105 ± 42 | 102 ± 35 | 106 ± 45 | 0.430 |
ACC time (min) | 75 ± 29 | 70 ± 22 | 77 ± 31 | 0.075 |
Statin Use and Postoperative Atrial Fibrillation
No AF | AF |
P
| |
---|---|---|---|
N = 123 |
N = 149 | ||
Age (years) | 63 ± 12 | 67 ± 10 | 0.002 |
Male, n (%) | 48 (39) | 82 (55) | 0.009 |
Previous history, n (%) | |||
NYHA I | 24 (21)a
| 13 (9) | |
NYHA II | 20 (17) | 35 (24) | |
NYHA III | 64 (55) | 82 (57) | |
NYHA IV | 9 (8) | 14 (10) | 0.047 |
AF | 12 (10) | 42 (28) | <0.001 |
PCI | 19 (15) | 12 (8) | 0.056 |
CABG | 16 (13) | 10 (7) | 0.079 |
Valve surgery | 29 (10) | 11 (13) | 0.198 |
Diabetes | 10 (8) | 17 (11) | 0.368 |
COPD | 17 (14) | 14 (10) | 0.219 |
Hypertension | 47 (38) | 63 (42) | 0.496 |
Pulmonary hypertension | 36 (32) | 71 (49) | 0.006 |
Laboratory | |||
Haemoglobin (mmol/l) | 8.6 ± 0.9 | 8.3 ± 1.1 | 0.019 |
Creatinine (μmol/l) | 104 (78–106)a
| 92 (78–102)a
| 0.947b
|
Cholesterol (mg/dl) | 211 ± 51 | 212 ± 47 | 0.781 |
Echocardiography | |||
Left atrial size (mm) | 47 ± 8 | 49 ± 3 | 0.048 |
LVEF (%) | 57 ± 13 | 57 ± 11 | 0.824 |
Drugs, n (%) | |||
ACE-I | 53 (43) | 74 (50) | 0.279 |
Beta-blocker | 33 (27) | 54 (36) | 0.098 |
Statin | 36 (29) | 43 (29) | 0.941 |
AAD | 13 (11) | 31 (21) | 0.023 |
Surgery, n (%) | |||
Emergency | 7 (6) | 5 (3) | 0.351 |
Aortic valve | 92 (75) | 97 (65) | 0.084 |
Mitral valve | 32 (26) | 46 (31) | 0.378 |
>1 valve | 5 (4) | 16 (11) | 0.037 |
Mechanical prosthesis | 95 (77) | 106 (73) | 0.384 |
ECC time (min) | 103 ± 43 | 106 ± 41 | 0.554 |
ACC time (min) | 74 ± 30 | 76 ± 28 | 0.668 |
P value | OR (95% CI) | |
---|---|---|
Age | 0.002 | 1.05 (1.017–1.074) |
Previous AF | 0.001 | 4.55 (1.905–10.856) |
Previous CABG | 0.029 | 0.24 (0.067–0.867) |
Pulmonary hypertension | 0.022 | 1.98 (1.102–3.557) |
Statin | 0.345 | 1.49 (0.651–3.403) |